Fig. 4
Effect of i.c.v. infusion of AZE in anesthetized and ventilated rats. MAP (A) is presented in the same manner as Fig. 1, with 2 h end MAP shown at B (ΔMAPCTRL(I) = -6 ± 6%, ΔMAPAZE(I) = -7 ± 2%, n = 4, P > 0.9, 1way ANOVA with Tukey’s post hoc analysis), as well as blood pCO2 (C, n = 4, P > 0.99 at 0 and 2 h, P = 0.7 at 1 h, 2way ANOVA with Tukey’s post-hoc analysis) and blood HCO3−, (D, n = 4, P < 0.001 for time variable, P = 0.1 for treatment variable, shown above bars, 2way ANOVA,). Effect of AZE i.c.v. (18 mM, 0.5 µl min−1; expected ventricular concentration ≤ 1 mM after dilution, see Methods) as a function of time is shown in E, with end 2 h change in F (n = 4, PCTRL−CTRL(I) = 0.6, PCTRL(I)−AZE(I) > 0.01, PAZE−AZE(I) > 0.9, 1way ANOVA with Tukey’s post-hoc analysis). Dark grey and light grey results are obtained from Fig. 1. Arrow indicates the start of i.c.v. infusion. MAP – mean arterial pressure, pCO2 – partial carbon dioxide pressure, ICP – intracranial pressure, CTRL – control, AZE – acetazolamide. (I) = rats receiving i.c.v. delivery of AZE. Data are shown as mean ± SD. **; P < 0.01, ns; not significant.